Oruka Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Oruka Therapeutics, Inc. (ORKA) reported Increase (Decrease) in Prepaid Expense and Other Assets of $4.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-10
- Oruka Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $4.64M, a 652.51% increase year-over-year.
- Oruka Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$461.00K, a 411.49% decline year-over-year.
- Oruka Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $805.00K.
- Oruka Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $2.40M.
- Oruka Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $3.97M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 5 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 8 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 11 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $4.18M 10-Q · filed 2026-08-10 | $4.99M derived: sum of 3 quarters · filed 2026-08-10 | $7.39M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | -$461.00K 10-Q · filed 2026-05-13 | $344.00K derived: sum of 2 quarters · filed 2026-05-13 | $2.75M derived: sum of 3 quarters · filed 2026-05-13 | $3.36M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | $805.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.21M derived: sum of 2 quarters · filed 2026-03-12 | $3.82M derived: sum of 3 quarters · filed 2026-08-10 | $3.97M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.02M derived: sum of 2 quarters · filed 2026-08-10 | $3.17M 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $617.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $765.00K 10-Q · filed 2026-08-10 | |||||
| 2025-03-31 | $148.00K 10-Q · filed 2026-05-13 | ||||||
| 2024-12-31 | $1.13M 10-K · filed 2026-03-12 | ||||||
| 2024-09-30 | $1.98M 10-Q · filed 2025-11-12 | ||||||
| 2024-06-30 | $1.72M 10-Q · filed 2025-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |